Faculty of Science and Natural Resources, University Malaysia Sabah, UMS Road, Kota Kinabalu 88400, Malaysia.
Medicina (Kaunas). 2022 Jun 19;58(6):826. doi: 10.3390/medicina58060826.
Background and Objectives: Noncommunicable diseases such as diabetes are strongly associated with the insulin resistance (IR) status of an individual. However, the prevalence of insulin resistance in Southeast Asia is poorly reported. Hence, this study investigated the prevalence of IR in Southeast Asia from the year 2016 to 2021. Materials and Methods: This study was carried out according to PRISMA guidelines. The literature search was conducted utilizing the PubMed and SCOPUS databases from the year 2016 to 2021 using the keywords ‘(insulin AND resistance) OR (insulin AND sensitivity) OR (prevalence OR incidence) AND (Malaysia OR Thailand OR Singapore OR Brunei OR Cambodia OR Indonesia OR Laos OR Myanmar OR Philippines OR Timor leste OR Vietnam)’. Funnel plot and publication bias were assessed using Egger’s tests. Data were expressed as the prevalence rate. Results: A total of 12 studies with 2198 subjects were considered in the meta-analysis. Significant heterogeneity (I2 > 94% and p-value < 0.001) was observed in the meta-analysis. The overall prevalence of IR in Southeast Asia was 44.3%, with Malaysia having the highest prevalence rate at 50.4%, followed by Indonesia at 44.2%. Bias was detected in the meta-analysis. It may be that reports published before the year 2016 met the study selection criteria, but were excluded from the meta-analysis. Conclusions: The results from the meta-analysis indicate that the prevalence of IR in Southeast Asia is very high. This provided insights for healthcare policy makers and public health officials in designing IR screening programs.
非传染性疾病（如糖尿病）与个体的胰岛素抵抗（IR）状态密切相关。然而，东南亚的胰岛素抵抗流行情况报道甚少。因此，本研究调查了 2016 年至 2021 年期间东南亚的胰岛素抵抗流行情况。
本研究根据 PRISMA 指南进行。使用 PubMed 和 SCOPUS 数据库，从 2016 年至 2021 年，使用关键词“（胰岛素和抵抗）或（胰岛素和敏感性）或（流行率或发生率）和（马来西亚或泰国或新加坡或文莱或柬埔寨或印度尼西亚或老挝或缅甸或菲律宾或东帝汶或越南）”进行文献检索。使用 Egger 检验评估漏斗图和发表偏倚。数据表示为流行率。
共纳入 12 项研究，包含 2198 名受试者。荟萃分析显示存在显著异质性（I2＞94%，p 值＜0.001）。东南亚的胰岛素抵抗总流行率为 44.3%，其中马来西亚的流行率最高（50.4%），其次是印度尼西亚（44.2%）。荟萃分析中存在偏倚。可能是 2016 年之前发表的报告符合研究选择标准，但被排除在荟萃分析之外。
荟萃分析结果表明，东南亚的胰岛素抵抗流行率非常高。这为医疗保健政策制定者和公共卫生官员制定胰岛素抵抗筛查计划提供了参考。
